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Original article
Cost-eﬀectiveness of asthma control: an economic appraisal of the
GOAL study
For most asthma patients, their asthma is not well
controlled and the disease causes a high degree of
disruption to their daily lives (1) despite the fact that it
is well known that treatment improves health related
quality of life (HRQoL) (2). As a consequence, some
commentators have argued that the deﬁnitions of asthma
control that are given in standard guidelines are unreal-
istic for the majority of asthma patients (3). The Gaining
Optimal Asthma controL (GOAL) study (4) was a 1 year,
stratiﬁed, randomized, controlled trial (protocol no.
SAM40027) that examined a strategy of managing
patients with uncontrolled asthma by aiming for total
control of their symptoms (5). The study showed that the
addition of salmeterol to ﬂuticasone propionate in a
single inhaler (SFC) leads to greater levels of control at
lower doses of inhaled corticosteroids and to an improve-
ment of HRQoL. Despite this clear demonstration of the
eﬀectiveness of SFC compared with ﬂuticasone propion-
ate (FP) alone, the combination product represents an
additional cost to the health system. It is natural
to consider, therefore, whether a strategy of aiming for
total control with SFC represents value for money in a
health system with competing demands on scarce
resources.
The aim of this analysis is to provide an economic
assessment of the GOAL study in order to estimate the
cost-eﬀectiveness of aiming for total control with SFC vs
FP alone. In particular, health outcomes are measured in
terms of quality adjusted life years (QALYs) in order that
the cost per QALY of treating asthma patients can be
compared with cost eﬀectiveness ratios in other disease
areas.
Methods
The economic analysis was conducted from the perspective of the
UK National Health Service and the analysis is designed to meet the
Background: The Gaining Optimal Asthma ControL (GOAL) study has shown
the superiority of a combination of salmeterol/ﬂuticasone propionate (SFC)
compared with ﬂuticasone propionate alone (FP) in terms of improving guide-
line deﬁned asthma control.
Methods: Clinical and economic data were taken from the GOAL study, sup-
plemented with data on health related quality of life, in order to estimate the cost
per quality adjusted life year (QALY) results for each of three strata (previously
corticosteroid-free, low- and moderate-dose corticosteroid users). A series of
statistical models of trial outcomes was used to construct cost eﬀectiveness
estimates across the strata of the multinational GOAL study including adjust-
ment to the UK experience. Uncertainty was handled using the non-parametric
bootstrap. Cost-eﬀectiveness was compared with other treatments for chronic
conditions.
Result: Salmeterol/ﬂuticasone propionate improved the proportion of patients
achieving totally and well-controlled weeks resulting in a similar QALY gain
across the three strata of GOAL. Additional costs of treatment were greatest in
stratum 1 and least in stratum 3, with some of the costs oﬀset by reduced health
care resource use. Cost-eﬀectiveness by stratum was £7600 (95% CI: £4800–
10 700) per QALY gained for stratum 3; £11 000 (£8600–14 600) per QALY
gained for stratum 2; and £13 700 (£11 000–18 300) per QALY gained for
stratum 1.
Conclusion: The GOAL study previously demonstrated the improvement in
total control associated with the use of SFC compared with FP alone. This
study suggests that this improvement in control is associated with cost-per-
QALY ﬁgures that compare favourably with other uses of scarce health care
resources.
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new UK National Institute for Health and Clinical Excellence
(NICE) reference case (6). The general principle was to report an
analysis based as closely as possible on the clinical trial. The
approach taken was to use the whole data set on resource use to
maximize use of the data available and therefore the power of the
resulting analysis with a UK indicator variable to adjust the analysis
for UK speciﬁc eﬀects. Due to the lack of direct data on utilities
suitable for calculating quality adjusted life-years (QALYs), the
analysis makes use of external data providing an algorithm for
linking the disease speciﬁc scale used in the trial to utility values in
order to provide QALY measures of health outcome. The ﬁrst
section below gives a brief description of the trial itself and the data
available for the analysis. This is followed by three sections des-
cribing the estimation of key components of the cost-eﬀectiveness
analysis: the proportion of time spent in diﬀerent categories of
control status; the cost of treatment and of other health service
resource use; and the conversion of quality of life outcomes to
utilities. The ﬁnal section describes how these elements are brought
together to provide cost per QALY values together with associated
conﬁdence intervals to represent uncertainty.
Study design and data
The GOAL study has recently been reported and full details of the
trial are published elsewhere (4). Brieﬂy, GOAL was a 52-week,
multinational, randomized, double-blind, controlled trial designed
to assess the eﬀectiveness of a predeﬁned stepwise programme of
increased dosages of FP or SFC in achieving asthma control.
The study comprised two phases. In phase I, patients were in the
dose-escalation phase where the dose of FP or SFC would be stepped
up if they failed to achieve total control in at least 7 weeks of an 8-
week assessment period. Patients entered the second (maintenance)
phase,where their dose remained at the level they reached at the endof
the ﬁrst phase. In total, 3416 patients from 44 countries were stratiﬁed
into three approximately equal groups and randomized between the
FP and SFC arms of the trial. The three strata related to patients use
of inhaled corticosteroids for 6-months prior to screening for study
entry: stratum 1, no inhaled corticosteroid; stratum 2, 500 lg or less
of beclomethasone dipropionate (BDP) or equivalent; or stratum 3,
>500–1000 lg or less of BDP or equivalent. Figure 1 provides an
overviewof the study designofGOALshowingboth the stepupphase
(phase I) and the maintenance phase (phase II) of treatment together
with the diﬀerence between the step up phase for strata 1 and 2 and
stratum 3.
Categorising control status and estimating proportion of time in
each state
For the purposes of this analysis, in each week of the trial patients
were classiﬁed into four mutually exclusive control categories: to-
tally controlled (TC); well controlled (WC); not well controlled
(NWC) but without exacerbation; and exacerbation (X). The TC
and WC categories were deﬁned based on treatment guidelines (5).
For those not achieving either of the control states in a given week,
two categories were distinguished because of the important eﬀect
asthma exacerbations have on both resource use and health status –
therefore, weeks involving an exacerbation (X) (deﬁned as deteri-
oration in asthma requiring treatment with an oral corticosteroid,
or an emergency department visit or hospitalization) were distin-
guished from those where control was lacking but no exacerbation
was experienced (NWC).
The categories of control status identiﬁed above were employed
as the dependent variable in a multinomial regression model (7–9) in
order to estimate the proportion of time patients spent in each
category of control while adjusting for the baseline strata and
treatment allocation of each patient.
Costs of study treatment and asthma management
For every week of the GOAL study, information on resource use
was collected for each patient under three main categories: secon-
dary care visits, primary care visits, and medication. Secondary care
information included: visits to emergency departments, length of
time (number of days) in ICU, outpatient visits; and inpatient days.
Primary care information included: general practitioner home visits
during the day and the night, visits to the primary care clinic, and
telephone calls to primary care clinic. Information on medications
used were distinguished between study drugs (daily cost for each
dosage level) and rescue medication use (per occasion cost). Unit
costs relating to each of these resources (for the 2003/2004 ﬁnancial
year) were taken from published sources for the UK (10).
For each patient and for each week in the study, the total cost of
treatment (study drugs only) and the cost of other health service
contacts (all primary/secondary care costs and rescue medication
use) was calculated. The approach to estimating costs was to
employ standard regression analysis on treatment cost and other
cost separately. This approach allowed the analysis to separately
estimate costs by stratum (important for treatment cost), facilitates
8-week control assessment
4-week control assessment
Phase I
Phase II
Visit     1      2      3 4 5 6 7      8
Week  -4 0 4 12 24 36 48     52
SFC 50/100
or FP 100
SFC 50/250
or FP 250
SFC 50/500A
B
or FP 500
Step 1
Step 2
Step 3
Visit     1      2      3 4 5 6 7      8
Week  -4 0 4 12 24 36 48     52
SFC 50/250
or FP 250
SFC 50/500
or FP 500
Step 1
Step 2
Figure 1. Design of the GOAL study showing the two phases of
step-up treatment and maintenance and showing the diﬀerence
in step-up treatment between strata 1 and 2 (A) and stratum 3
(B). FP, ﬂuticasone propionate; SFC, salmeterol/ﬂuticasone
propionate in combination.
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the linking of costs to the control status of patients (important for
other health service costs) and allows adjustment for the UK
analysis using the full GOAL data set.
Impact on health related quality of life
If economic analyses are to be useful to decision makers, the out-
comes reported must be in a form that is comparable across disease
areas. The most popular outcome for this purpose is the quality-
adjusted life-year (or QALY) which weights survival by a utility
score which reﬂects the health status of the patient (11). This utility
weight is anchored at 1 (representing perfect health) and 0 (repre-
senting death). Although the GOAL study did not include a utility
measure as part of its design, it did include a disease speciﬁc
instrument, the Asthma Quality of Life Questionnaire (AQLQ) (12)
completed at baseline and at each clinic visit in the study. A map-
ping algorithm exists to translate AQLQ scores into a utility score
suitable for economic appraisal (S. Macran and P. Kind, personal
communication). Using this algorithm, the AQLQ scores were
translated into utilities which were entered into a regression analysis
that allowed the utility scores to be directly associated with control
status categories observed in the trial.
Cost-effectiveness and uncertainty
The cost-eﬀectiveness of aiming for total control with SFC is esti-
mated by bringing together the estimates of proportion of time
spent in each state, the quality of life in each state, the cost asso-
ciated with each state and the cost of treatment from each of the
equations described above separately for each of the strata in the
original study. Uncertainty is handled statistically through uncer-
tainty in the estimated coeﬃcients of each regression model. The
non-parametric approach of bootstrapping (13) is employed in or-
der to account for potential correlation between the regression
models comprising the analysis and to calculate conﬁdence intervals
for cost-eﬀectiveness ratios (14).
Results
Control status
Table 1 shows the proportion of time during the 52-weeks
of the trial that patients spent in the four control
categories separately by treatment arm and by baseline
stratum. The table shows the observed data (ﬁrst three
rows) and predictions from a multinomial model (the
second three rows) with allocation group and stratum as
explanatory variables (all signiﬁcant predictors of control
status with P < 0.001) and it is clear that the model
provides a good ﬁt to the observed data. Treatment with
SFC clearly has a positive impact on asthma control
irrespective of the baseline stratum of the patient.
Resource use costs
Regression models were run separately for study treat-
ment and other health service costs. For costs due to
study treatment, allocation to the combination arm was
expected to increase costs but that the absolute diﬀerence
would diﬀer across the strata. Therefore, the regression
model for treatment cost included treatment allocation
and stratum as explanatory variables (including interac-
tion eﬀects between treatment and strata). The resulting
predictions of (weekly) treatment cost are presented in
Table 2, which show that SFC results in additional costs
compared with FP alone.
The regression for other health service costs is reported
in Table 3 and shows that control status was found to be
a highly signiﬁcant predicator of this type of cost
(P < 0.001). Importantly, the addition of stratum and
treatment allocation had no signiﬁcant eﬀect once control
status was accounted for, suggesting that the use of SFC
has no eﬀect on other health service resource use beyond
the improvement in control status. Furthermore, it was
found that including a UK adjustment for the cost of
Table 1. Observed and predicted percentages of time spent in categories of control
status by strata and treatment allocation
FP arm SFC arm
TC WC NWC X TC WC NWC X
Observed
Stratum 1 32 33 34 1 40 32 28 0
Stratum 2 22 31 46 1 35 34 30 1
Stratum 3 17 29 52 2 26 33 40 1
Modelled
Stratum 1 31 32 37 1 42 32 26 0
Stratum 2 24 32 44 1 34 34 32 1
Stratum 3 17 29 52 2 26 32 40 1
FP, fluticasone propionate; SFC, salmeterol/fluticasone propionate in combination;
TC, totally controlled; WC, well controlled; NWC, not well controlled (no exacer-
bation); X, exacerbation.
Table 3. Other health service costs as a function of control status and adjusting for
the UK experience
Regression model Weekly costs
Cost (£) SE Cost (£) SE
TC (constant) 0.02 0.30 0.02 0.30
WC 0.14 0.25 0.16 0.28
NWC 1.09 0.28 1.11 0.28
X 52.35 0.89 32.29 5.62
X * UK )20.08 5.68
TC, totally controlled; WC, well controlled; NWC, not well controlled (no exacer-
bation); X, exacerbation; UK, United Kingdom indicator variable.
Table 2. Treatment costs by treatment allocation and by stratum
FP arm SFC arm
Cost (£) SE Cost (£) SE
Stratum 1 4.98 0.09 8.29 0.09
Stratum 2 5.60 0.09 8.37 0.09
Stratum 3 7.17 0.09 9.21 0.09
FP, fluticasone propionate; SFC, salmeterol/fluticasone propionate in combination.
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exacerbation was highly signiﬁcant (P < 0.001) suggest-
ing that on average UK patients experiencing an
exacerbation are treated less resource intensively (a
reduced cost of £20) than the average resource use
associated with an exacerbation in the trial. The predicted
cost of a week in each control status category, with the
cost of an exacerbation week adjusted to reﬂect the UK,
are shown alongside the regression results in Table 3
(second column). It is clear from these results that cost
decreases with improved control and the most signiﬁcant
healthcare costs are associated with exacerbations.
Health-related quality of life and QALYs
The approach to estimating utilities for the calculation of
QALYs mirrors the regression analysis of other cost
above. The utility values mapped from the AQLQ scores
formed the explanatory variable in a regression with
control status as explanatory. The results of this regres-
sion model are presented in Table 4 which includes a
dummy variable for UK patients (all explanatory varia-
bles were signiﬁcant predictors of quality of life at
P < 0.001). In contrast to the other health service cost
regression, adding in treatment as an explanatory
variable resulted in a marginally signiﬁcant utility gain
of 0.01 (P ¼ 0.044) even when controlling for control
status, suggesting there may be additional beneﬁts of
treatment not captured by the simple categorization of
control used in this paper. In the analysis presented here,
this additional treatment beneﬁt is ignored, making the
analysis conservative with respect to the value of the
combination product. Similarly, stratum 3 was associated
with a small, but signiﬁcant (P < 0.001), reduction in
utility of )0.02 which is not accounted for in the analysis
presented here.
Cost-effectiveness
To estimate cost-eﬀectiveness for each of the strata in the
GOAL study the four models presented in Tables 1–4
were combined. The mechanics of this approach are
illustrated in Table 5 which presents all of the informa-
tion from the previous tables by control status, stratum
and allocation arm. Costs and QALYs are estimated
within each stratum and by allocation arm through a
process of weighted averaging over control status. The
ﬁnal column of Table 5 summarizes the diﬀerences
between the arms.
The incremental analysis and cost-per-QALY calcula-
tions are reproduced in Table 6 using the information
from Table 5, but also presenting conﬁdence intervals for
each reported value derived from the bootstrap analysis.
The cost-eﬀectiveness results by strata were estimated as
£7600 (95% CI: £4800–10 700) per QALY gained for
stratum 3; £11 000 (£8600–14 600) per QALY gained for
stratum 2; and £13 700 (£11 000–18 300) per QALY
Table 4. Health related quality of life utilities by control status
Regression model Weekly utilities
Utility SE Utility SE
TC (constant) 0.902 0.003 0.946 0.011
WC )0.045 0.002 0.900 0.011
NWC )0.104 0.003 0.842 0.011
X )0.216 0.007 0.729 0.013
UK 0.044 0.011
TC, totally controlled; WC, well controlled; NWC, not well controlled (no exacer-
bation); X, exacerbation; UK, United Kingdom indicator variable.
Table 5. Estimating the incremental costs and QALYs by stratum
FP arm SFC arm
DifferenceTC WC NWC X Weighted Average TC WC NWC X Weighted average
Stratum 1
Status distribution (%) 31 32 37 1 42 32 26 0
Treatment cost (£) 4.98 4.98 4.98 4.98 4.98 8.29 8.29 8.29 8.29 8.29 3.31
Other health care costs (£) 0.02 0.16 1.11 32.29 0.63 0.02 0.16 1.11 32.29 0.45 )0.18
HRQoL/QALYs 0.946 0.900 0.842 0.729 0.892 0.946 0.900 0.842 0.729 0.903 0.012
Stratum 2
Status distribution (%) 24 32 44 1 34 34 32 1
Treatment cost (£) 5.60 5.60 5.60 5.60 5.60 8.37 8.37 8.37 8.37 8.37 2.77
Other health care costs (£) 0.02 0.16 1.11 32.29 0.83 0.02 0.16 1.11 32.29 0.61 )0.22
HRQoL/QALYs 0.946 0.900 0.842 0.729 0.884 0.946 0.900 0.842 0.729 0.896 0.012
Stratum 3
Status distribution (%) 17 29 52 2 26 32 40 1
Treatment cost (£) 7.17 7.17 7.17 7.17 7.17 9.21 9.21 9.21 9.21 9.21 2.05
Other health care costs (£) 0.02 0.16 1.11 32.29 1.25 0.02 0.16 1.11 32.29 0.95 )0.31
HRQoL/QALYs 0.946 0.900 0.842 0.729 0.874 0.95 0.90 0.84 0.73 0.886 0.012
FP, fluticasone propionate; SFC, salmeterol/fluticasone propionate in combination; TC, totally controlled; WC, well controlled; NWC, not well controlled (no exacerbation);
X, exacerbation.
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gained for stratum 1. These results are illustrated in
Fig. 2, which also shows the cost-eﬀectiveness of a
number of technologies that have been recommended
for use in the UK NHS.
Discussion
This paper presents the cost-eﬀectiveness of SFC relative
to FP alone for achieving total control of asthma, based
on the GOAL study. Since the GOAL study had a
stratiﬁed design, the cost-eﬀectiveness analysis was pre-
sented for each stratum, based on a series of statistical
relationships estimated from the data. The results showed
cost per QALY values that diﬀer across the diﬀerent
strata of the GOAL study. In order to judge whether
these ﬁgures represent good value, comparison with other
uses of scare health care resources is required.
In the UK, the main public sector body for considering
the value for money of treatments to be made available
on the NHS is the National Institute of Health and
Clinical Excellence (NICE). Although the oﬃcial position
is that there is no single cost-eﬀectiveness threshold below
which NICE considers cost-eﬀectiveness to be proven, a
threshold can be inferred from previous decisions. For
example, Devlin and Parkin assembled a table of reported
cost-eﬀectiveness results and the associated guidance
decision from NICE based on the information available
from NICE’s website. By conducting a logistic regression
of these decisions they concluded that cost-eﬀectiveness
does explain NICE decision making, along with other key
factors such as uncertainty and the burden of disease (15).
More recently, it has been suggested that
NICE would be unlikely to reject a technology with a ratio in the range
of £5000–£15 000/QALY solely on the grounds of cost-ineffectiveness
(16).
A selection of decisions for which the NICE guidance
was positive, taken from the Devlin and Parkin paper (12)
are presented alongside the GOAL results in Fig. 2,
together with the range over which NICE would be
unlikely to reject a technology on cost-eﬀectiveness
grounds. Figure 2 is strongly suggestive that aiming for
TC with SFC would be considered cost-eﬀective for all
strata in GOAL in the context of NICE decision making
in the UK.
The approach to estimating cost-eﬀectiveness by
stratum highlights a methodological issue when con-
ducting economic analysis alongside a stratiﬁed trial.
The approach reported here is based on a series of
statistical equations for the components of the economic
analysis that adjust for treatment allocation and stra-
tum. An alternative approach would have been to
present the analysis separately for each stratum. How-
ever, such an approach would have involved splitting the
data with consequent loss of power. By modelling the
eﬀect of the stratum directly, the full power of the data
was retained.
Nevertheless, this increased power comes through the
extra structural assumptions imposed on the analysis.
The aim in this paper was to make those assumptions as
transparent as possible to allow the reader to judge their
appropriateness. For example, the results from the cost-
regression analyses suggest the important predictors of
costs diﬀer between treatment costs and other health
service resource use. For treatment costs, it is the trial
allocation arm and baseline stratum that are the import-
ant predictors of cost. By contrast, these variables are not
predictive of other health service costs once control status
is added to the regression. The results for the HRQoL
regression are less deﬁnitive. In particular, it was reported
in the text that both treatment allocation and stratum 3
were signiﬁcantly predictive of HRQoL independently of
control status. Nevertheless, in the reported cost-eﬀect-
iveness analysis, these modest additional eﬀects of treat-
Table 6. Cost-per-QALY by stratum of GOAL
Difference
Point estimate Lower 95% limit Upper 95% limit
Stratum 1
Total costs (£) 163 147 177
Total QALYs 0.0118 0.0094 0.0143
ICER (£) 13 700 11 000 18 300
Stratum 2
Total costs (£) 132 114 147
Total QALYs 0.0120 0.0094 0.0145
ICER (£) 11 000 8600 14 600
Stratum 3
Total costs (£) 90 61 109
Total QALYs 0.0118 0.0093 0.0141
ICER (£) 7600 4800 10 700
£430: Smoking cessation programme
£28 500: ICDs 
£25 000: Laparoscopic hernia repair
(recurrent)
£5 000: Asthma inhalers for children
£22 500: Sibutramine for obesity 
£15 000: Drug therapy for Alzheimer’s
£12 500: Methylphenidate for ADHD
£-
£5 000
£10 000
£15 000
£20 000
£25 000
£30 000
3 2 1
Stratum
Co
st
 p
er
 Q
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Figure 2. Results for the cost-eﬀectiveness of aiming for total
control by stratum including a selection of technologies recently
recommended for use in the UK NHS by the National Institute
of Health and Clinical Excellence (NICE) (15). The shaded area
illustrates the range over which it has been suggested that NICE
are unlikely to reject an intervention purely on cost-eﬀectiveness
grounds (16). ICD, implantable cardioverter deﬁbrillator;
ADHD, attention deﬁcit and hyperactivity disorder.
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ment and stratum 3 were excluded in order to simplify the
assumptions of the analysis.
An additional issue is that the GOAL study was a
multinational trial, but that the focus of this analysis was
the cost-eﬀectiveness in the UK. The approach used was
to employ the whole data set on resource use in order to
maximize the power of the resulting analysis, but to
employ a UK indicator variable to adjust the analysis for
UK speciﬁc eﬀects. This approach highlighted that, on
average, the cost of treating an exacerbation (deterior-
ation in asthma requiring treatment with an oral corti-
costeroid or an emergency department visit or
hospitalization) in the UK was £20 below the overall
cost in the trial.
The use of the non-parametric bootstrap allows con-
ﬁdence intervals to be calculated for the estimates of cost-
eﬀectiveness based on combining a series of statistical
relationships estimated from the data. These conﬁdence
intervals represent uncertainty related to sampling vari-
ation and include potential correlation structure between
the estimated equations. However, the conﬁdence inter-
vals do not include uncertainty related to the algorithm
that links the AQLQ disease speciﬁc instrument to the
utility scores suitable for calculating QALYs, as this
algorithm was based on data external to the trial.
Conclusion
The GOAL study has shown that a strategy of aiming for
total control leads to better outcomes for the majority of
patients and that these outcomes translate to improve-
ments in quality-adjusted life years. The use of SFC
compared with FP alone results in a cost-per-QALY ratio
that compares favourably with other uses of scarce health
care resources that have recently been recommended by
the NICE in the UK.
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